Abstract
Lymphoid-tyrosine phosphatase (Lyp), encoded by the PTPN22 gene, is a member of the protein tyrosine phosphatase family enzymes. Human genetics studies have shown that a single-nucleotide polymorphism in PTPN22 is often mutated in patients suffering from autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosis. Because of its critical role in the regulation of T-cell Receptor (TCR) signaling pathways, Lyp recently emerged as a candidate target for therapy of autoimmune diseases. Herein, we review the structure and splice isoforms of Lyp, the biochemistry of the disease-predisposing allele, discuss the function of the phosphatase in TCR signaling and the association with human autoimmune diseases. Especially, we summarized recent progress in the development of Lyp inhibitors, intending to provide a basis for the Lyp-based treatment of autoimmunity. Moreover, the emphasis and direction for future study of Lyp in autoimmune diseases were prospected.
Keywords: Autoimmune diseases, lymphoid-tyrosine phosphatase, Lyp, PTPs, inhibitor.
Current Drug Targets
Title:Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Volume: 15 Issue: 3
Author(s): Jintong Du, Yu Qiao, Lele Sun and Xiuwen Wang
Affiliation:
Keywords: Autoimmune diseases, lymphoid-tyrosine phosphatase, Lyp, PTPs, inhibitor.
Abstract: Lymphoid-tyrosine phosphatase (Lyp), encoded by the PTPN22 gene, is a member of the protein tyrosine phosphatase family enzymes. Human genetics studies have shown that a single-nucleotide polymorphism in PTPN22 is often mutated in patients suffering from autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosis. Because of its critical role in the regulation of T-cell Receptor (TCR) signaling pathways, Lyp recently emerged as a candidate target for therapy of autoimmune diseases. Herein, we review the structure and splice isoforms of Lyp, the biochemistry of the disease-predisposing allele, discuss the function of the phosphatase in TCR signaling and the association with human autoimmune diseases. Especially, we summarized recent progress in the development of Lyp inhibitors, intending to provide a basis for the Lyp-based treatment of autoimmunity. Moreover, the emphasis and direction for future study of Lyp in autoimmune diseases were prospected.
Export Options
About this article
Cite this article as:
Du Jintong, Qiao Yu, Sun Lele and Wang Xiuwen, Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases, Current Drug Targets 2014; 15 (3) . https://dx.doi.org/10.2174/13894501113146660236
DOI https://dx.doi.org/10.2174/13894501113146660236 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Phenylpyazoleanilides as Potent Inhibitor of IL-15 Dependent T Cell Proliferation. Part 2: Discovery of a New Drug Candidate, Y-320
Letters in Drug Design & Discovery Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis
Current Drug Targets Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Gluten-dependent Intestinal Autoimmune Response
Current Pharmaceutical Design Evaluating the Relationship Between Serum Level of Interleukin-6 and Rheumatoid Arthritis Severity and Disease Activity
Current Rheumatology Reviews UCSF Small Molecule Discovery Center: Innovation, Collaboration and Chemical Biology in the Bay Area
Combinatorial Chemistry & High Throughput Screening May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets Capsaicin and Its Analogues: Structure-Activity Relationship Study
Current Medicinal Chemistry Thromboprophylaxis in Medical Patients: An Update
Vascular Disease Prevention (Discontinued) Therapeutic Targeting of Chemokines with Monoclonal Antibodies
Current Immunology Reviews (Discontinued) Prevention of Allergic Disease Development and Symptoms by Food Factors
Current Pharmaceutical Design Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Cyclo-Oxygenase (COX) Inhibiting Nitric Oxide Donating (CINODs) Drugs: A Review of Their Current Status
Current Topics in Medicinal Chemistry Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets Mediterranean Diet and Longevity
Current Nutrition & Food Science 3D-QSAR Study on Ring Substituted Imidazoles for Their Antitubercular Activity
Letters in Drug Design & Discovery New Strategies for the Prevention and Treatment of Systemic and Local Bone Loss; from Pathophysiology to Clinical Application
Current Pharmaceutical Design Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry